title: Idarubicin in acute leukemia: results of US trials.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: E
authors.initials: E
authors.lastname: Berman
authors.forename: V
authors.initials: V
authors.lastname: Raymond
authors.forename: T S
authors.initials: TS
authors.lastname: Gee
authors.forename: S J
authors.initials: SJ
authors.lastname: Kempin
authors.forename: S
authors.initials: S
authors.lastname: Gulati
authors.forename: M
authors.initials: M
authors.lastname: Andreeff
authors.forename: J
authors.initials: J
authors.lastname: Gabrilove
authors.forename: C W
authors.initials: CW
authors.lastname: Young
authors.forename: B D
authors.initials: BD
authors.lastname: Clarkson
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*
chemical_list: D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin